Current management of tuberous sclerosis complex

被引：45
作者：
Krueger D.A. [1 ]
Franz D.N. [1 ,2 ]
机构：
[1] Tuberous Sclerosis Clinic, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
[2] Department of Neurology, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45339-3039
来源：
Pediatric Drugs | 2008年 / 10卷 / 5期
关键词：
Amitriptyline; therapeutic use; Angiomyolipoma; treatment; Antiepileptic drugs; Astrocytoma; Children; Clonidine; Corticotropin; Felbamate; Infantile spasms;
D O I：
10.2165/00148581-200810050-00004
中图分类号：
学科分类号：
摘要：
Tuberous sclerosis complex (TSC) is an important cause of epilepsy, autism, and renal and pulmonary disease in children and adults. The clinical course of TSC and the prognosis and appropriate therapy for TSC patients are often different than that for individuals with epilepsy, renal tumors, or interstitial lung disease from other causes. This article reviews the current therapeutic recommendations for medical and surgical management of neurologic, renal, and pulmonary manifestations of TSC. In addition, recent clinical trials using inhibitors of the mammalian target of rapamycin (mTOR) have demonstrated regression of astrocytomas, angiofibromas, and angiomyoliomas, as well as improved pulmonary function in persons with TSC. © 2008 Adis Data Information BV. All rights reserved.
引用
收藏
页码：299 / 313
页数：14
相关论文
共 119 条
[1]  
Tuberous sclerosis complex: From basic science to clinic phenotypes, (2003)
[2]  
Crino P., Nathanson K., Henske E., The tuberous sclerosis complex, N Engl J Med, 355, 13, pp. 1345-1356, (2006)
[3]  
Yates J., Tuberous sclerosis, Eur J Hum Genet, 14, 10, pp. 1065-1073, (2006)
[4]  
Identification and characterization of the tuberous sclerosis gene on chromosome 16, Cell, 75, 7, pp. 1305-1315, (1993)
[5]  
van Slegtenhorst M., deHoogt R., Hermans C., Et al., Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34, Science, 277, 5327, pp. 805-808, (1997)
[6]  
Zhang Y., Gao X., Saucedo L., Et al., Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins, Nature Cell Biol, 5, 6, pp. 578-581, (2003)
[7]  
Ma L., Teruya-Feldstein J., Bonner P., Et al., Identification of S664 TSC2 phosphorylation as a marker for Erk-mediated mTOR activation in tuberous sclerosis and human cancer, Cancer Res, 67, 15, pp. 7106-7112, (2007)
[8]  
Ravikumar B., Vacher C., Berger Z., Et al., Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease, Nat Genet, 36, 6, pp. 585-595, (2004)
[9]  
Paccalin M., Pain-Barc S., Pluchon C., Et al., Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease, Dement Geriatr Cogn Disord, 22, 4, pp. 320-326, (2006)
[10]  
Xu L., Alafuzoff I., Soininen H., Et al., Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain, FEBS J, 272, 16, pp. 4211-4220, (2005)
12345678910